Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading

Nuclear Medicine Communications

Volumn 23, Issue 6, 2002, Pages 545-550

  Zhao, S ^a   Kuge, Y ^a   Tsukamoto, E ^a   Mochizuki, T ^a   Kato, T ^a   Hikosaka, K ^b   Nakada, K ^b   Hosokawa, M ^b   Kohanawa, M ^b   Tamaki, N ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Hokkaido University   (Japan)

Author keywords

Glucose; Glucose transporters; Inflammation; Tumour; F fluoro d glucose positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; ISOPHANE INSULIN; TURPENTINE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; GASTROCNEMIUS MUSCLE; GLUCOSE TRANSPORT; HEPATOMA CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MYOSITIS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS;

EID: 0036258170     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200206000-00006     Document Type: Article

References (47)

1. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
2. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195: 345-352.
3. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-1932.
4. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171: 21-26.
5. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
6. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
7. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-1969.
8. Wahl RL, Zasadny K, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
9. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
10. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492-1495.
11. 18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13: 829-831.
12. 18F] FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14: 486-487.
13. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
14. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 1996; 10: 185-191.
15. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15: 796-801.
16. Meyer MA, Frey KA, Schwaiger M. Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med 1993; 18: 682-684.
17. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998; 25: 1238-1243.
18. 125I-HAS. Eur J Nucl Med 1999; 26: 333-341.
19. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36: 1301-1306.
20. Pauwels EKJ, McCready VR, Stoot JHMB, van Deurzen DFP. The mechanism of accumulation of tumor-localising radiopharmaceuticals. Eur Nucl Med 1998; 25: 277-305.
21. 14C]-glucose during chemotherapy in murine Lewis lung tumor. Int J Radiat Appl Instrum [B] 1992; 19: 55-63.
22. 18F]-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-1161.
23. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21: 827-834.
24. Golshani-Hebroni SG, Bessman SP. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr 1997; 29: 331-338.
25. Bell GI, Burant CF, Takeda J, Gould GM. Structure and function of mammalian facilitative sugar transporters. J Biol Chem 1993; 268: 19161-19164.
26. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell cancer. J Nucl Med 1999; 40: 556-565.
27. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-1735.
28. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-1348.
29. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-2985.
30. Boado RJ, Black KL, Pardridge WN. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 1994; 27: 51-57.
31. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 1997; 17: 2747-2750.
32. Younes M, Brown RW, Stephenson M, Cagle PT. Over-expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-1051.
33. Suzuki T, Iwaki A, Katagiri H, et al. Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. Eur J Biochem 1999; 262: 534-540.
34. Mochizuki T, Tsukamoto E, Kuge Y, et al. Difference of FDG uptake and GLUT expression between inflammation and malignant tumor. J Nucl Med 2000; 41: 257P.
35. Minn H, Nuutila P, Lindholm P, et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer 1994; 73: 1490-1498.
36. Torizuka T, Fisher SJ, Wahl RL. Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology 1997; 203: 169-172.
37. Torizuka T, Fisher SJ, Brown RS, Wahl RL. Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 1998; 208: 499-504.
38. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992; 183: 643-647.
39. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34: 355-359.
40. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993; 34: 1-6.
41. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesion. Eur J Nucl Med 2001; 28: 730-735.
42. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990; 17: 273-279.
43. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer therapy: a review. Nucl Med Commun 1998; 19: 97-105.
44. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human panctreatic tumors compared with increased FDG accumulation in a PET study. J Nucl Med 1997; 38: 1337-1344.
45. James DE. Targeting of the insulin-regulatable glucose transporter (GLUT-4). Biochem Soc Trans 1994; 22: 668-670.
46. Peters JH, Hausen P. Effect of phytohemagglutinin on lymphocyte membrane transport. 2. Stimulation of ‘facilitated diffusion’ of 3-O-methyl-glucose. Eur J Biochem 1971; 19: 509-513.
47. Uchiyama T, Kamagata Y, Yan XY, et al. Study of the biological activities of toxic shock syndrome toxin-1: II. Induction of the proliferative response and the interleukin 2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin. Clin Exp Immunol 1987; 68: 638-647.